Price$2.63+0.33 (+14.35%)
2026-03-052026-06-08
News · 26 weeks53-75%
2025-12-142026-06-07
Mix2690d
- Insider9(35%)
- SEC Filings9(35%)
- Other6(23%)
- Earnings2(8%)
Latest news
25 items- INSIDERDirector Hirsch Douglas Joseph was granted 4,642 shares, increasing direct ownership by 2% to 247,502 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERDirector Bruehlman Ronald E was granted 4,642 shares, increasing direct ownership by 4% to 133,918 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- PRGoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare CostsNew $14.99-per-month membership brings together free and low-cost generic medications, affordable online care visits, and savings across dental, vision, labs and imaging Brief Summary: GoodRx launched GoodRx Companion, a new $14.99-per-month subscription to lower everyday healthcare costs Provides access to free and low-cost generic medications, affordable online care, and savings on routine healthcare services Expands GoodRx's subscription strategy as consumers face tighter insurance restrictions and higher out-of-pocket healthcare cost GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subs
- INSIDERChief Accounting Officer Chan Thomas (Tc) converted options into 5,575 shares and covered exercise/tax liability with 2,838 shares, increasing direct ownership by 274% to 3,737 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDEROfficer Mcginnis Christopher A covered exercise/tax liability with 19,726 shares and converted options into 44,779 shares, increasing direct ownership by 16% to 177,616 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- SECSEC Form 144 filed by GoodRx Holdings Inc.144 - GoodRx Holdings, Inc. (0001809519) (Subject)
- INSIDERSEC Form 4 filed by Chief Accounting Officer Chan Thomas (Tc)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- SECSEC Form 10-Q filed by GoodRx Holdings Inc.10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- PRGoodRx Reports First Quarter 2026 ResultsPharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.0% Net cash provided by operating activities of $11.8 million "We deliver
- INSIDERNew insider Chan Thomas (Tc) claimed ownership of 1,000 shares (SEC Form 3)3 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- PRGoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes PatientsEligible self-pay patients can access the oral diabetes treatment for as low as $149 per month Brief Summary: GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month Available at GoodRx's nationwide pharmacy network Adds an oral option to the Ozempic treatment portfolio GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk's Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide. "As Novo Nordisk brings the Ozempic pill to market, we're f
- SECSEC Form DEFA14A filed by GoodRx Holdings Inc.DEFA14A - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECSEC Form DEF 14A filed by GoodRx Holdings Inc.DEF 14A - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- PRGoodRx Announces Date for First Quarter 2026 Earnings Release and Conference CallGoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor
- INSIDERSEC Form 4 filed by Mcginnis Christopher A4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- INSIDERSEC Form 4 filed by Barnes Wendy Lynn4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
- PRGoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay PriceExpands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss Brief Summary: Wegovy® HD is now available on GoodRx at a self-pay price of $399 per month Pricing scales to $798 for two-month supply and $1,197 for three-month supply Available at pharmacies nationwide through GoodRx Consumers can determine eligibility and obtain a prescription through GoodRx for Weight Loss GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month.
- PRGoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies NationwideEligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx Brief Summary: GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx GoodRx is also offering self-pay pricing for Zepbound® (tirzepatide) KwikPen® starting at $299 per month Foundayo and Zepbound KwikPen are available through GoodRx's nationwide pharmacy network GoodRx is helping pharmaceutical manufacturers deliver consumer-direct pricing at scale from day one GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today a
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
- SECGoodRx Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
- INSIDERDirector Rey-Giraud Agnes exercised 192,185 shares at a strike of $0.47, gifted 75,219 shares and received a gift of 75,219 shares, increasing direct ownership by 313% to 352,852 units (SEC Form 4)4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
GDRX FAQ
7 questionsWhat does GoodRx Holdings Inc. do?
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies...Where does GDRX stock trade?
GoodRx Holdings Inc. (GDRX) is listed on NASDAQ.What sector and industry is GDRX in?
GoodRx Holdings Inc. operates in the Technology sector, EDP Services industry.When did GoodRx Holdings Inc. go public?
GoodRx Holdings Inc. (GDRX) completed its IPO in 2020.What are analysts saying about GDRX?
GoodRx Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral on 2026-02-27. Recent price targets range from $275.00 to $1000.00.What companies are similar to GDRX?
Notable peers in the same industry include NEE (NextEra Energy Inc.), PDD (PDD Holdings Inc.), INFY (Infosys Limited), DASH (DoorDash Inc.), WDAY (Workday Inc.). Compare GDRX side-by-side with any of them on Quantisnow.How can I track GDRX on Quantisnow?
Quantisnow aggregates GoodRx Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GDRX to receive live email and push alerts on every new disclosure.